Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Quinagolide

Criteria

Inclusion Criteria

1. Signed Informed Consent Form, prior to screening evaluations

2. In good physical and mental health

3. Pre-menopausal females between the ages of 21-37 years (both inclusive) at the time of randomisation

4. Infertility for at least 1 year before randomisation, except for proven bilateral tubal infertility

Exclusion Criteria

1. Any clinically significant systemic disease

2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

3. History of recurrent miscarriage

4. Undiagnosed vaginal bleeding